JP2022526720A5 - - Google Patents
Info
- Publication number
- JP2022526720A5 JP2022526720A5 JP2021555415A JP2021555415A JP2022526720A5 JP 2022526720 A5 JP2022526720 A5 JP 2022526720A5 JP 2021555415 A JP2021555415 A JP 2021555415A JP 2021555415 A JP2021555415 A JP 2021555415A JP 2022526720 A5 JP2022526720 A5 JP 2022526720A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2019107136A RU2742000C2 (ru) | 2019-03-13 | 2019-03-13 | Выделенный альтернативный внутриклеточный сигнальный домен химерного антигенного рецептора и включающий его химерный антигенный рецептор |
| RU2019107136 | 2019-03-13 | ||
| PCT/RU2020/000136 WO2020185121A2 (ru) | 2019-03-13 | 2020-03-13 | Выделенный альтернативный внутриклеточный сигнальный домен химерного антигенного рецептора и включающий его химерный антигенный рецептор |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022526720A JP2022526720A (ja) | 2022-05-26 |
| JPWO2020185121A5 JPWO2020185121A5 (https=) | 2023-03-17 |
| JP2022526720A5 true JP2022526720A5 (https=) | 2023-03-17 |
| JP7735186B2 JP7735186B2 (ja) | 2025-09-08 |
Family
ID=72425914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021555415A Active JP7735186B2 (ja) | 2019-03-13 | 2020-03-13 | キメラ抗原受容体の代替の細胞内シグナル伝達ドメイン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12540169B2 (https=) |
| EP (1) | EP3974444A4 (https=) |
| JP (1) | JP7735186B2 (https=) |
| KR (1) | KR20220157861A (https=) |
| CN (1) | CN114206918A (https=) |
| RU (1) | RU2742000C2 (https=) |
| WO (1) | WO2020185121A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201713078D0 (en) * | 2017-08-15 | 2017-09-27 | Adaptimmune Ltd | T Cell Modification |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| WO2022081486A1 (en) * | 2020-10-12 | 2022-04-21 | Sorrento Therapeutics, Inc. | Cd19-directed chimeric antigen receptor constructs |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| CA2386270A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| WO2014153114A1 (en) * | 2013-03-14 | 2014-09-25 | Fred Hutchinson Cancer Research Center | Compositions and methods to modify cells for therapeutic objectives |
| PL3546572T3 (pl) * | 2013-05-13 | 2024-07-22 | Cellectis | Chimeryczny receptor antygenowy swoisty względem cd19 i jego zastosowania |
| WO2015069922A2 (en) * | 2013-11-06 | 2015-05-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
| MX383150B (es) * | 2014-06-02 | 2025-03-13 | Us Health | Receptores quiméricos de antígeno que tienen como diana a cd-19. |
| EP3393504B1 (en) * | 2015-12-22 | 2025-09-24 | Novartis AG | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
| WO2018132506A1 (en) | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
-
2019
- 2019-03-13 RU RU2019107136A patent/RU2742000C2/ru active
-
2020
- 2020-03-13 KR KR1020217032967A patent/KR20220157861A/ko not_active Ceased
- 2020-03-13 US US17/438,398 patent/US12540169B2/en active Active
- 2020-03-13 EP EP20770459.4A patent/EP3974444A4/en active Pending
- 2020-03-13 CN CN202080035754.4A patent/CN114206918A/zh active Pending
- 2020-03-13 WO PCT/RU2020/000136 patent/WO2020185121A2/ru not_active Ceased
- 2020-03-13 JP JP2021555415A patent/JP7735186B2/ja active Active